Jubilant Ingrevia Q4 FY26 Earnings Call Transcript Released; Board Recommends Final Dividend of ₹2.5/Share
Jubilant Ingrevia released its Q4 FY26 earnings call transcript. The company reported its highest quarterly revenue and EBITDA in 14 quarters. The Board recommended a final dividend of ₹2.5 per share. Q4 revenue was ₹1,179 crore (up 12% YoY) and EBITDA ₹172 crore (up 11% YoY). The company anticipates sequential growth from Q1 FY27.
The release of the earnings call transcript and the dividend announcement are significant for investors, providing detailed insights into the company's performance and future strategy. The positive financial results and outlook suggest a medium impact on investor sentiment and potential stock movement.
The company reported strong financial performance with record quarterly revenue and EBITDA, a healthy dividend recommendation, and positive outlook for future growth, indicating a positive sentiment.
Jubilant Ingrevia Limited has released the transcript of its Investors' Conference Call for the audited standalone and consolidated financial results for the Quarter and Financial Year ended March 31, 2026. The call, held on May 26, 2026, featured management including Chairman Mr. Shyam Bhartia, CEO and Managing Director Mr. Deepak Jain, and CFO Mr. Varun Gupta.
During the call, the company reported a healthy performance for Q4 and FY26, noting the highest quarterly revenue and EBITDA in 14 quarters. Specialty Chemicals achieved its best quarterly revenue at ₹516 crore. The company highlighted its effective handling of the Middle East crisis with no force majeure or production loss. Key achievements included the dispatch of products from a new agro CDMO facility and the acquisition of Remidex to boost the Human Nutrition business.
The Board recommended a final dividend of ₹2.5 per share, bringing the total FY26 dividend to ₹5 per share, with a total cash outflow of ₹79.8 crore. Management expressed confidence in sustained growth across segments for FY27, driven by Specialty Chemicals and Nutrition, with a recovery expected in Acetyls. They anticipate sequential growth in revenue and EBITDA starting from Q1 FY27.
For Q4 FY26, revenue stood at ₹1,179 crore, up 12% year-on-year, with EBITDA at ₹172 crore, up 11% year-on-year. Net debt to EBITDA improved to 0.99x. Specialty Chemicals revenue grew 6% year-on-year to ₹516 crore, with EBITDA at ₹139 crore and margins maintained at 27% for six quarters. FY26 revenue for Specialty Chemicals was ₹1,937 crore, up 7%, and EBITDA was ₹510 crore, up 21%.
The Nutrition business reported segment revenue of ₹230 crore, up 21% year-on-year, with EBITDA at ₹32 crore. FY26 revenue for Nutrition was ₹790 crore and EBITDA ₹100 crore. The Chemical Intermediates business revenue was ₹433 crore, up 15% year-on-year.
Management discussed the progress of their 'Pinnacle Journey,' noting strong volume growth, a customer-centric approach leading to over 100 opportunities with a potential of ₹3,500 crore, and significant lean savings. They also highlighted investments in R&D and strengthening leadership with senior hires. The acquisition of Remidex Pharma was completed to enhance the Human Nutrition premixes portfolio. The company reiterated its target of achieving 3x revenue and 4x EBITDA in the next four years, driven by fine chemicals, CDMO opportunities, and the nutrition portfolio, with potential upside from acetyls.
What to do with a filing like this
Jubilant Ingrevia Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Ingrevia Limited. Read the original for the full detail.